A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma

Affiliations

¹ Washington University School of Medicine, Division of Oncology, St. Louis, MO. tfehnige@wustl.edu.
² Washington University School of Medicine, Division of Oncology, St. Louis, MO.
³ Washington University School of Medicine, Division of Biostatistics, St. Louis, MO.
⁴ Wake Forest University School of Medicine, Section of Hematology and Oncology, Winston-Salem, NC.
⁵ Emory University School of Medicine, Atlanta, GA.
⁶ Hackensack University Medical Center, Division of Lymphoma, Hackensack, NJ.
⁷ Medical College of Wisconsin, Hematology and Oncology, Milwaukee, WI.
⁸ Washington University, Mallinckrodt Institute of Radiology, Alvin J. Siteman Cancer Center, St. Louis, MO.
⁹ Washington University School of Medicine, Division of Oncology, St. Louis, MO. nbarlet@wuslt.edu.

Clinical Trial

Todd A Fehniger et al. Haematologica. 2024.

. 2024 Mar 1;109(3):953-957.

doi: 10.3324/haematol.2022.282246.

¹ Washington University School of Medicine, Division of Oncology, St. Louis, MO. tfehnige@wustl.edu.
² Washington University School of Medicine, Division of Oncology, St. Louis, MO.
³ Washington University School of Medicine, Division of Biostatistics, St. Louis, MO.
⁴ Wake Forest University School of Medicine, Section of Hematology and Oncology, Winston-Salem, NC.
⁵ Emory University School of Medicine, Atlanta, GA.
⁶ Hackensack University Medical Center, Division of Lymphoma, Hackensack, NJ.
⁷ Medical College of Wisconsin, Hematology and Oncology, Milwaukee, WI.
⁸ Washington University, Mallinckrodt Institute of Radiology, Alvin J. Siteman Cancer Center, St. Louis, MO.
⁹ Washington University School of Medicine, Division of Oncology, St. Louis, MO. nbarlet@wuslt.edu.

No abstract available

Figures

1. Connors JM, Jurczak W, Straus DJ, et al. . Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378(4):331-344. - PMC - PubMed
1. Herrera AF, LeBlanc ML, Castellino SM, et al. . SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). J Clin Oncol. 2023;41(Suppl 17):LBA4-LBA4.
1. Badar T, Epperla N, Szabo A, et al. . Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Adv. 2020;4(1):41-54. - PMC - PubMed
1. Gribben JG, Fowler N, Morschhauser F. Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol. 2015;33(25):2803-2811. - PMC - PubMed
1. Fehniger TA, Larson S, Trinkaus K, et al. . A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood. 2011;118(19):5119-5125. - PMC - PubMed